Design Therapeutics reports four-week RESTORE-FA trial gains for DT-216P2 in Friedreich ataxia

Design Therapeutics, Inc.

Design Therapeutics, Inc.

DSGN

0.00
  • Design Therapeutics reported four-week interim results from its Phase 1/2 RESTORE-FA trial of DT-216P2 in Friedreich ataxia, with the dataset based on 16 patients who completed weekly intravenous dosing across four dose levels.
  • The trial showed dose-related clinical improvement across multiple measures, with patient-reported fatigue also improving and the effect persisting beyond the dosing period.
  • Biomarkers indicated increased endogenous frataxin activity in blood and muscle, supporting the drug’s proposed disease-targeting mechanism.
  • DT-216P2 was generally well-tolerated, with no serious adverse events or treatment discontinuations; the main drug-related finding was transient liver enzyme elevations in some patients.
  • The results support a move toward registrational development, with an update on the planned path targeted for the fourth quarter of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Design Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605180700PRIMZONEFULLFEED9721851) on May 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.